Recro Pharma Secondary Offering (UPDATE)

By Chris Lange Updated Jan 12, 4:58PM EST · Published Dec 8, 11:50AM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Recro Pharma Secondary Offering (UPDATE) — © Thinkstock

This story has been amended due to updated information from the filing. Recro Pharma Inc. (NASDAQ: REPH) saw its shares fall on Thursday after the company announced an update to its secondary offering.

An amended SEC filing showed that the company intends to offer roughly 5.72 million shares and was valued at up to $40 million based upon the last closing price of $6.99 per share. The original filing from a week earlier showed that the offering was originally valued at $57.5 million based upon an $8.00 prior share price.

It’s worth noting that this is coming after the company recently won in its late-stage IV metoxicam trial. The sole book-running manager and underwriter for this offering is Piper Jaffray.

This revenue-generating, specialty pharmaceutical company is primarily focused on developing innovative products for hospitals and ambulatory care settings. Its lead product candidate, injectable meloxicam, is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor that has successfully completed five clinical trials in the treatment of moderate to severe pain, including a two recently completed pivotal Phase 3 clinical trials.

[nativounit]

As injectable meloxicam is not in the opioid class of drugs, the firm believes it will overcome many of the issues associated with commonly prescribed opioid therapeutics, including addiction, misuse/diversion, respiratory distress and constipation while maintaining analgesic, or pain relieving, effect.

Additionally, Recro is leverage its formulation expertise to develop and manufacture pharmaceutical products using its proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. These collaborations result in revenue streams including royalties, profit sharing, research and development and manufacturing, which support continued operations for its subsidiaries as well as research and development of proprietary product candidates.

The company intends to use the net proceeds from this offering to fund the New Drug Application (NDA) filing and regulatory approval process and the initiation of commercial activities for IV meloxicam, its planned IV meloxicam Phase 3B program, investments in pipeline product candidates and for general corporate purposes. Recro will need additional capital to fund the completion of its commercial infrastructure, including milestone payments and post-launch activities for IV meloxicam, subject to regulatory approval.

Shares of Recro Pharma were down 5% at $6.63 in midday trading on Thursday, with a consensus analyst price target of $22.20 and a 52-week trading range of $5.59 to $12.50.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.